Paper Details

  1. Home
  2. Paper Details

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Author: , BaertschMarc-Andrea, BeckerNatalia, BesemerBritta, BrossartPeter, FenkRoland, GoernerMartin, GoldschmidtHartmut, GraevenUllrich, HabermehlChristina, HaenelMathias, HielscherThomas, HillengassJens, HoseDirk, JauchAnna, KleinStefan, LindemannHans W, LuntzSteffen, MartinHans, Müller-TidowCarsten, NogaiAxel, NoppeneyRichard, RaabMarc-Steffen, ReimerPeter, SalwenderHans, SauerSandra, ScheidChristoph, SchlenzkaJana, Schmidt-HieberMartin, SeckingerAnja, WeiselKatja

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, open-label, phase III trial compares the effectiveness of a transplant arm (including high-dose chemotherapy and autologous stem cell transplantation) versus a control arm (continuous lenalidomide) for treating relapsed and/or refractory multiple myeloma (RRMM).
Paper Details　
Original Abstract of the Article :
The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/s41375-020-0948-0

データ提供：米国国立医学図書館（NLM）

Salvage Autologous Transplant and Lenalidomide Maintenance: A Treatment Strategy for Relapsed Multiple Myeloma

Multiple myeloma is a type of blood cancer that can be challenging to treat. This study investigates the effectiveness of a treatment strategy that combines a salvage autologous transplant with lenalidomide maintenance for patients with relapsed multiple myeloma. The study compares this approach to a control group that received continuous lenalidomide treatment.

A Comprehensive Treatment Approach for Relapsed Multiple Myeloma

The study found that while the salvage autologous transplant and lenalidomide maintenance approach did not significantly prolong progression-free survival (PFS) or overall survival (OS) compared to continuous lenalidomide treatment on an intention-to-treat basis, patients who actually received the transplant had a significantly better PFS and OS.

Health Considerations and Lifestyle Changes

This study highlights the complexities of treating relapsed multiple myeloma. It underscores the importance of careful patient selection and individualized treatment plans.

Dr. Camel's Conclusion

Just as a camel navigates a vast desert landscape, navigating the complex terrain of cancer treatment requires a tailored approach. This study explores the potential of a combined treatment strategy for relapsed multiple myeloma, emphasizing the importance of individualizing treatment plans and considering the unique needs of each patient.

Date :
  1. Date Completed 2021-04-30
  2. Date Revised 2021-07-21
Further Info :

Pubmed ID

32694619

DOI: Digital Object Identifier

10.1038/s41375-020-0948-0

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.